About Divergent protein kinase domain 1C
Divergent protein kinase domain 1C (DIPK1C) is a protein
from Homo sapiens identified by UniProt accession
Q0P6D2, 419 residues long.
MolForge cross-references it against 0 known binders and
15 disease associations.
Target properties
| Protein name | Divergent protein kinase domain 1C |
| UniProt accession | Q0P6D2 |
| Gene | DIPK1C |
| Organism | Homo sapiens |
| Length | 419 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (15)
Diseases linked to this target (Open Targets).
- attention deficit hyperactivity disorder · score 0.08
- attention deficit-hyperactivity disorder 8 · score 0.07
- schizophrenia 15 · score 0.07
- Phelan-McDermid syndrome · score 0.05
- X-linked non-syndromic intellectual disability · score 0.04
- Potocki-Lupski syndrome · score 0.04
- testosterone measurement · score 0.03
- serum metabolite measurement · score 0.02
- theta wave measurement · score 0.02
- refractive error measurement · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q0P6D2-F1 | alphafold | PREDICTED | 86.38 | — |
Amino-acid sequence (419 residues)
MARAAGARGP AGWCRRRGRC GRGTLLAFAA WTAGWVLAAA LLLRAHPGVL SERCTDEKSR RILAALCQDY QGGTLAGDLC EDLCVAGELL FQRCLHYNRG KKVLQADWRG RPVVLKSKEE AFSSFPPLSL LEEEAGEGGQ DMPEAELLLM VAGEVKSALG LELSNSSLGP WWPGRRGPRW RGQLASLWAL LQQEEYVYFS LLQDLSPHVL PVLGSCGHFY AVEFLAAGSP HHRALFPLDR APGAPGGGQA KAISDIALSF LDMVNHFDSD FSHRLHLCDI KPENFAIRSD FTVVAIDVDM AFFEPKMREI LEQNCTGDED CNFFDCFSRC DLRVNKCGAQ RVNNNLQVIC DKIFRHWFSA PLKSSAVSFQ LQLQLQEAVQ ECADPGVPSG NTRRAASSVF WKLRQLLQAT LRELQEAEK
Explore Divergent protein kinase domain 1C with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets